PDF(Pubmed)
Abstract：
In recent years, there has been a substantial increase in the development of antitussive therapies and the first new therapy, gefapixant has been licenced in Europe. This review describes current unlicenced treatments for chronic cough and details treatments currently in development for refractory chronic cough and cough in idiopathic pulmonary fibrosis, as well as compounds previously explored.
摘要：
近年来,镇咳疗法和第一种新疗法的发展大幅增加，Gefapixant已在欧洲获得许可。这篇综述描述了目前对慢性咳嗽的未经许可的治疗方法，并详细介绍了目前正在开发的难治性慢性咳嗽和特发性肺纤维化咳嗽的治疗方法。以及以前探索的化合物。
